01 December 2006
Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: A review
Giuliano Rizzardini, Amedeo CapettiMed Sci Monit 2006; 12(12): RA269-276 :: ID: 469713
Abstract
The major trials conducted on treatment simplifi cation included large portions of patients who had previously received monotherapy or dual therapy and were likely to have relevant mutations of resistance at baseline. These studies concluded that simplifi cation was safe (especially when this
population was excluded), with some additional risk of viral failure for subjects simplifi ed to abacavir- based regimens. On the other hand, induction-maintenance studies and other studies which involved only patients who had started HAART as the fi rst-line showed that simplifi cation to abacavir
was as safe as continuation of the original regimen and better accepted by the patients. The largest randomized studies of simplifi cation that allowed extrapolation of data on the population of subjects who had never received suboptimal therapy were reviewed. Four studies failed to show signifi cant differences in effi cacy between treatment arms, while two detected signifi cant differences in favor of the continuation arms. Simplifi cation to abacavir led to signifi cant decreases in cholesterol and triglyceride levels and to slight improvements in quality of life. No variations in body shape were detected, although the duration was probably insuffi cient and most studies
did not involve adequate technology (i.e. DEXA, CT). Other, smaller studies are also presented in the review, selected for their particular design or analysis, which may contribute to a better understanding of the setting in which simplifi cation may be a feasible option. Choosing the adequate timing and the correct patient characteristics, simplifi cation to abacavirbased
regimens is safe and prevents metabolic consequences of therapy.
Keywords: Dideoxynucleosides - adverse effects, Antiretroviral Therapy, Highly Active, Anti-HIV Agents - adverse effects, Drug Resistance, Viral - genetics, Drug Therapy, Combination, Drug Tolerance, HIV Infections - drug therapy, HIV-1 - genetics, Multicenter Studies as Topic, Mutation, Randomized Controlled Trials as Topic, Safety
939 1
Editorial
01 December 2023 : Editorial
Editorial: Outbreaks of Post-Pandemic Childhood Pneumonia and the Re-Emergence of Endemic Respiratory InfectionsDOI: 10.12659/MSM.943312
Med Sci Monit 2023; 29:e943312
In Press
01 Dec 2023 : Clinical Research
Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective St...Med Sci Monit In Press; DOI:
30 Nov 2023 : Review article
Decoding the Neurological Sequelae of General Anesthesia: A ReviewMed Sci Monit In Press; DOI:
30 Nov 2023 : Clinical Research
Enhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Comparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...Med Sci Monit In Press; DOI:
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292